Quidel Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Quidel's estimated annual revenue is currently $1.9B per year.(i)
  • Quidel received $140.0M in venture funding in August 2012.
  • Quidel's estimated revenue per employee is $2,325,871
  • Quidel's current valuation is $4.8B. (January 2022)

Employee Data

  • Quidel has 804 Employees.(i)
  • Quidel grew their employee count by -2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$42310M14061023%N/A$226.6B
Add Company

Quidel Corporation (Nasdaq: QDEL) is a California-based manufacturer of diagnostic healthcare solutions serving to enhance the health and well being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Quidel is 35 years young, with commercialized products in the healthcare market since 1984. Originally known for lateral flow products used in physicianâ's offices, our product lines have expanded through robust product development to include tests in infectious disease and reproductive health that are used in hospitals, reference labs, and clinics as well. Our current products fall generally into these categories: (1) lateral flow, where we are market leaders in infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); and (4) molecular diagnostic products. Whether at our headquarters in San Diego, California, at our research and manufacturing operations in Ohio, Massachusetts, and Germany, or through our Commercial organization around the world, the Company is delivering a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody testing to molecular diagnostic tests that further improve the quality of healthcare.

keywords:Biotechnology,Enterprise Software,Healthcare,Medical Devices,Medical Diagnostics,Pharmaceuticals

N/A

Total Funding

804

Number of Employees

$1.9B

Revenue (est)

-2%

Employee Growth %

$4.8B

Valuation

N/A

Accelerator

Quidel News

2022-04-17 - Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?

Quidel Corporation QDEL is scheduled to report first-quarter 2022 results on May 4, after the closing bell. In the last-reported quarter,...

2022-03-30 - Quidel preliminary Q1 revenue beats Street on COVID-19 test ...

Quidel on Thursday announced preliminary first-quarter revenue in the range of $990 million to $1 billion, beating the Street's estimate of...

2022-03-30 - Quidel Announces Preliminary Revenue for First Quarter 2022

Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid...

2021-08-10 - PRESS RELEASE : LivLyme Foundation Founder Olivia Goodreau to Discuss Perils of Lyme Disease in Free Webinar Hosted by Industry-Leading Quidel Corporation

DGAP-News: Quidel Corporation LivLyme Foundation Founder Olivia Goodreau to Discuss Perils of Lyme Disease in Free Webinar Hosted by Industry-Leading Quidel Corporation 2021-08-10 / 15:00 The issuer is solely responsible for the content of this announcement. ------------------------------------- ...

2021-07-12 - PRESS RELEASE : New Website Created by Quidel Corporation Provides Consumers With Information and Easy-to-Understand Answers Regarding Lyme Disease

DGAP-News: Quidel Corporation New Website Created by Quidel Corporation Provides Consumers With Information and Easy-to-Understand Answers Regarding Lyme Disease 2021-07-12 / 15:00 The issuer is solely responsible for the content of this announcement. =------------------------------------------- ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$232.2M80910%N/A
#2
$188.8M84351%N/A
#3
$213.7M84812%N/A
#4
$134.2M86615%N/A
#5
$170.9M872-9%N/A

Quidel Funding

DateAmountRoundLead InvestorsReference
2008-10-10$120.0MUndisclosedArticle
2012-08-14$140.0MUndisclosedBank of America NAArticle